Company intelligence / Profile preview

EverNov Medicines

Guangdong Sheng, Chinaeverestmedicines.com ↗

Ownership: Private
Development stage: Other

Overview

EverNov’s lead asset, EVER-4010001/Roblitinib/FGF401, an oral small molecule FGFR4 antagonist originally from Novartis, has been in Phase 1/2 clinical trials for liver cancer and other FGFR4/KLB-positive solid tumors. The most recent available data indicate ongoing or recently suspended early-phase studies in China and internationally. Everest Medicines expects NDA/BLA submission for Roblitinib in liver cancer after 2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

roblitinib

Partnerships

Novartis (licensing partner for FGF401)Pembrolizumab manufacturer implied by trial design

Beyond the preview

Go deeper on EverNov Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EverNov Medicines.